Vertex (VRTX) Slumps on VX-809 Data Presentation

October 11, 2012 11:59 AM EDT
Vertex Pharmaceuticals (Nasdaq: VRTX) shares are slumping as data for VX-809 is being presented. Vertex didn't see significant change in patient weight gain, with the 56-day study not being long enough.

Additionally, according to a biotech follower, investors shouldn't expect tight correlation between sweat chloride reduction and FEV1. Sweat chloride "just a biomarker."

Data is being presented by lead study investigator Michael P. Boyle, M.D., F.C.C.P. For more, click here.

Shares are down 6 percent Thursday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Insiders' Blog, Momentum Movers

Add Your Comment